iRadimed Corporation is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in Orlando, FL. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $84 million and a profit of $22 million (its filed statements).
Product businessSurgical & Medical Instruments & ApparatusOrlando, FLfilings since 20059 of 9 filed
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.5 out of ten, 9 of 9 metrics filed: past 5.3 out of ten, present 7.3 out of ten, future 6.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 3.8 out of ten. 1 warning event since 2017; the latest 2024-06-07. 38th percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.2 out of ten. +11.1% a year over 10 filed years; profitable in 10 of 10. 52nd percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 7.6 out of ten. Share count grew 0.6% a year. 65% of cash flow returned. Insiders: 129 sales, 0 purchases. 76th percentile among 40 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 8.5 out of ten. ROE 24%: 24¢ of profit per shareholder dollar. Leverage 13%: owes 13¢ per asset dollar. 85th percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 6.7 out of ten. top 33% of 109 in its family; net margin 26.8%. 67th percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.6 out of ten. top 44% of 90 in its family for leadership; chief executive since 2020. 56th percentile among 90 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 6.8 out of ten. top 32% of 104 in its family for room to expand. 68th percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 7.4 out of ten. top 26% of 105 in its family for growth drivers. 74th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 4.7 out of ten. bottom 47% of 88 in its family for expectations against reality. 47th percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-06 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-31 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-05-01 (on EDGAR). Newest filing: Form 4, 2026-09-25. Filings on record since 2005. Read from EDGAR 2026-10-12.
Who runs it
Susi, Roger E. (CEO, President, Chairman); Glenn, John (CFO); Chiprin, Jeff (Chief Commercial Officer); Kiani, Joe E (director); Allen, Monty K (director); Scharen-Guivel, Hilda Frederique (director); Hawkins, James B (director). 7 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.